X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of “Hold” from Brokerages

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned an average recommendation of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $8.50.

XFOR has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Friday, March 27th. Finally, Guggenheim initiated coverage on shares of X4 Pharmaceuticals in a research note on Monday, March 9th. They issued a “buy” rating and a $12.00 target price for the company.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR opened at $4.33 on Thursday. X4 Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $6.63. The company has a debt-to-equity ratio of 0.41, a current ratio of 10.16 and a quick ratio of 9.98. The firm has a market cap of $393.68 million, a price-to-earnings ratio of -1.00 and a beta of 0.32. The company has a fifty day moving average price of $3.80 and a 200-day moving average price of $3.72.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.14. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. The firm had revenue of $2.57 million during the quarter, compared to analyst estimates of $1.68 million. As a group, equities research analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in XFOR. Empery Asset Management LP purchased a new position in shares of X4 Pharmaceuticals in the 4th quarter worth about $35,804,000. Perceptive Advisors LLC purchased a new position in shares of X4 Pharmaceuticals in the 4th quarter worth about $25,258,000. Bain Capital Life Sciences Investors LLC boosted its holdings in shares of X4 Pharmaceuticals by 227.0% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock worth $31,870,000 after buying an additional 5,530,866 shares during the last quarter. Kalehua Capital Management LLC purchased a new position in shares of X4 Pharmaceuticals in the 4th quarter worth about $14,891,000. Finally, Braidwell LP purchased a new position in shares of X4 Pharmaceuticals in the 4th quarter worth about $13,476,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.